Edumed sro

Náchod 551 01

3 studies enrolling now · 14 studies all time

What they study most

Atherosclerotic Cardiovascular Disease, Cardiovascular Risk, Chronic Heart Failure, Chronic Kidney Disease, Diabetes Mellitus, Type 2, Diabetes, Type 2, Dyslipidemia, Heart Failure, Heart Failure With Mildly Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction, Inflammation, Obesity

Studies at this site

• Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity — Recruiting now
• A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity — Recruiting now
• Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity — Recruiting now
• ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation — Completed
• A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D) — Running, not enrolling
• Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity — Running, not enrolling
• Evaluate Efficacy, Safety and Tolerability of JTT-861 in Subjects With Heart Failure With Reduced Ejection Fraction — Completed
• A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE) — Completed
• Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial — Running, not enrolling
• A Study of Olezarsen (ISIS 678354) Administered to Participants With Severe Hypertriglyceridemia — Completed
• CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG) — Running, not enrolling
• Pemafibrate to Reduce Cardiovascular OutcoMes by Reducing Triglycerides IN patiENts With diabeTes (PROMINENT) — Stopped early
• Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease — Running, not enrolling
• Flecainide Acetate Inhalation Solution for Cardioversion of Recent-Onset, Symptomatic Atrial Fibrillation — Stopped early